Matrix-assisted laser desorption/ionization (MALDI) tissue imaging mass spectrometry is particularly promising among the numerous applications of mass spectrometry. It is used for probing and analyzing the spatial arrangement of a wide range of molecules, including proteins, peptides, lipids, drugs, and metabolites, directly in thin slices of tissue. In the field of proteomics, the technology avoids tedious and time-consuming extraction and fractionation steps classically required for sample analysis. MALDI imaging mass spectrometry is increasingly recognized as a powerful method for clinical proteomics, particularly in cancer research. The technology has particular potential for the discovery of new tissue biomarker candidates, classification of tumors, early diagnosis or prognosis, elucidating pathogenesis pathways, and therapy monitoring. Over recent years, MALDI imaging mass spectrometry has been used for molecular profiling and imaging directly in male and female reproductive tissues. This review will consider some of the recent publications in the field, addressing a range of issues covering embryo development, gene expression product profiling during gametogenesis, and seeking and identifying biomarkers of reproductive cancers. The wealth of advances in mass spectrometry imaging will inevitably attract biologists and clinicians as the advantages and power of this technology become more widely known. This review will also discuss bottlenecks and the many technical issues that remain to be resolved before laboratories in the field can adopt the technology. We foresee that MALDI imaging mass spectrometry will have a major impact in reproductive research by opening new avenues to the understanding of various molecular mechanisms and the diagnosis of reproductive pathologies.
INTRODUCTION AND OVERVIEW
Determination of the function and regulation of genes and their products is one of the key objectives of human biology. The advances in molecular biology and genomics over the last 20 years have greatly improved our knowledge and understanding of many complex biological processes within living organisms. This has also made it possible to elucidate key molecular entities involved in these processes. However, our understanding of the molecular basis of most aspects of reproduction, particularly in the human, is still poor. There has been significant progress recently in the large-scale analysis of male and female reproductive function, mainly deepening our insight into normal and pathological gametogenesis. Indeed, several laboratories have exploited progress with genome sequencing and microarrays by carrying out genome-wide expression studies, leading to the identification of hundreds of genes differentially expressed within the testis, the ovary, or during embryo development (for reviews see [1] [2] [3] ). Although not at the same exhaustive scale as gene expression studies, proteomics-based approaches has already made a significant contribution to our understanding of molecules significant to reproductive function. Indeed, the development of tools for high-throughput protein identification has allowed, in a few laboratories, differential protein profiling expression studies and the systematic analysis of proteomes from various species, based on either entire organs or isolated cells (for reviews see [4, 5] ). However, describing the spatial distribution of proteins within an organism, organ, or cell at various stages of its development remains difficult. Molecular tags are classically used for visualizing species of interest (e.g., chemical stains, antibodies) but their use requires a priori knowledge of the target entities, and the number of targets that can be monitored simultaneously is limited.
Matrix-assisted laser desorption/ionization (MALDI) tissue imaging mass spectrometry (IMS), exemplified by the work of Caprioli et al. [6] , Stoeckli et al. [7] , and Chaurand et al. [8, 9] , is an exciting application of mass spectrometry for protein identification and analysis. IMS is a powerful technique that combines the multichannel measurement capability of a mass spectrometer with a surface sampling process; it allows probing and analyzing the spatial arrangement of a wide range of molecules, including proteins, peptides, lipids, drugs, and metabolites, directly in thin slices of tissue. It yields information concerning the relative abundance and spatial distribution of target molecules, allowing correlation between ion-specific images and histological features observed by light microscopy. IMS is increasingly recognized as a powerful approach in clinical proteomics, particularly in cancer research [10] . The technology is potentially powerful for the discovery of new tissue biomarker candidates, classification of tumors, early diagnosis and prognosis, elucidating pathogenesis pathways, and therapy monitoring [11] .
The identification of protein biomarkers in easily accessible biological fluids has potential for the development of minimally invasive procedures for early diagnostics [10, 12] , but the analysis of body fluids such as plasma, serum, and urine is complicated by their wide dynamic range of protein expression, the variation in their composition, and their sensitivity to sample handling. Many serum biomarkers are not very specific or sensitive [10] . Analysis of tissue homogenates using the well-established and extremely powerful conventional techniques of differential proteomics has the advantage of the lower dynamic range of protein expression in such samples than in biological fluids; however, this approach suffers from an oversimplification of tissue morphology as a ''black vs. white''-type contrast. In particular, cancer tissues contain several different cell types at various developmental stages [13] . The direct analysis of cancer tissues by IMS preserves the spatial proteomic information. Consequently, it is very promising for the discovery of highly specific biomarkers.
IMS has some unique advantages that can reinforce and complement conventional imaging techniques. In contrast to immunohistochemistry (IHC), IMS allows the simultaneous spatial localization of hundreds of proteins in tissue sections without prior knowledge of tissue composition and without the need for time-consuming processing steps, specific probes, or labeling of analytes that can alter their native localization or function [14] . These multiplex capabilities are also particularly useful in the field of biomarker detection, particularly as in many cases single proteins are insufficiently reliable diseasespecific markers. A panel of biomarker candidates may potentially provide an unambiguous diagnosis [15, 16] .
METHODOLOGY
The workflow of an IMS experiment is presented in Figure  1 . Immediately upon collection, tissue samples are loosely wrapped in an aluminum foil to preserve their morphology and snap frozen in liquid nitrogen. Frozen tissues can be stored at À808C to avoid degradation. A frozen tissue section (8-14 lm thick) is prepared using a cryostat and thaw mounted onto either a flat metallic MALDI target or a conductive indium tin oxide (ITO) slide. It is essential to avoid any contact between the specimen-embedding medium and the cryostat blade because it could contaminate the section, resulting in poorer quality data [17] . After drying, the slides or targets are immersed in washing solutions. For protein analysis, washing solutions are generally composed of alcohol and water to remove interfering salts and lipids. The composition of washing solutions may need to be optimized according to the tissue [18, 19] . For lipid analysis, the washing step is not required. After drying, the matrix can be either applied uniformly onto the whole section (for imaging) or spotted onto various regions of interest (for profiling) [17] . In both cases, the matrix can be applied manually, but automated devices are strongly recommended for better reproducibility. Matrix deposition is a crucial step because it has to ensure the extraction of the analytes from the tissue and their cocrystallization with the matrix molecules without causing delocalization through the section.
For imaging experiments, the matrix solution is nebulized into small droplets with an average size around 20 lm using a sprayer and applied onto the whole section in successive layers. The tissue section can then be analyzed in a MALDI mass spectrometer [20] . It is irradiated with the UV laser of the MALDI source with a raster width of 20-80 lm corresponding to the lateral resolution. For each irradiated spot, a mass spectrum is generated. At the end of the acquisition, the localization of each peak detected can be represented on the optical image of the section to reconstitute a molecular image.
For profiling or low lateral resolution imaging experiments, the matrix is spotted as discrete droplets with a diameter of 150-300 lm onto the region of interest using a piezoelectric or acoustic microspotter [21] [22] [23] . A mass spectrometry spectrum is then acquired from each matrix spot. More intense and rich signals are generally obtained with microspotters because of a better extraction, but currently high lateral resolution can only be achieved using automated sprayers.
IMS is ideally performed with freshly frozen tissue to minimize protein degradation and to avoid sample contamination by medium embedded in the specimen. However, formalin-fixed, paraffin-embedded (FFPE) tissue is the standard for long-term preservation of samples archived in biopsy banks at medical centers. Thus, because of the growing demand for the analysis of FFPE tissues by MALDI imaging, appropriate methods have been developed [24] [25] [26] [27] . FFPE tissue sections are cut, fixed onto ITO slides, and dewaxed in xylene. Formalin fixation induces cross-linking, thus creating a complex network of linked proteins. Consequently, an ontissue enzymatic digestion is performed [28] and can be combined with antigen retrieval that partially reverses the cross-linking [25, 29] . Reproductive tissues were used as the model for these developments (breast MCF7 xenograft sections, FFPE human breast and ovarian cancer tissues). Mangé et al. [30] investigated new alternatives for clinical tissue-sample archives; using various human tissues including prostate, they demonstrated the compatibility of RCL2/CS100, a non-cross-linking organic fixative, with proteomic analyses and IMS. Protein profiles similar to those obtained from freshfrozen tissue sections were observed, although there was a loss of sensitivity.
SUCCESS WITH MALDI IMS FOR CANCER RESEARCH
Over recent years, IMS has been used for molecular profiling and imaging experiments directly with male and female reproductive tissues. In this section, we will describe some recent work that used MALDI IMS for identification of novel cancer biomarkers in reproductive organs.
Ovarian Cancer Biomarkers
Ovarian cancer accounts for 4% of female cancers worldwide with over 190 000 new cases diagnosed each year, mainly in Europe and the United States [31] . Ovarian cancer is the most lethal of gynecologic malignancies. Currently, due to the absence of specific clinical symptoms during early stage disease, diagnosis is often delayed until the disease is well advanced (stages III/IV) with a 5-year survival of only 50% [32] . CA125 is the most extensively studied biomarker for ovarian cancer, and is approved for monitoring response to treatment and possible recurrence. Unfortunately, the sensitivity of CA125 alone for early-stage disease is insufficient for it to be used as a diagnostic biomarker for screening. HE4, another biomarker of ovarian cancer approved for monitoring LAGARRIGUE ET AL. recurrence, is more sensitive than CA125 for early-stage disease [33] . However, even the combination of both CA125 and HE4 lacks the sensitivity required for diagnostic screening [12] . Consequently, the discovery and validation of new biomarkers for early diagnosis of ovarian cancer would be extremely beneficial and would help increase the survival rate. As stated above, classical proteomic technologies have potential in this field [12] , but IMS is a very attractive alternative approach [10, 34] .
The potential of MALDI imaging for the discovery of new putative biomarkers of ovarian cancer has already been demonstrated. Lemaire et al. identified a new candidate protein biomarker only present in ovary carcinoma (grade III/IV) by comparison, through statistical analysis, of the MALDI profiles of 25 ovary carcinomas and 23 benign tissues [35] . This potential biomarker is a C-terminal fragment of the 11S proteasome activator complex, named PA28 or Reg-alpha. The specific localization of Reg-alpha in epithelial cells of carcinoma tissues was also confirmed by both IHC with an anti-Ct Reg-alpha antibody and a specific MALDI imaging approach named tag mass. This approach was based on the use of a primary antibody directed against the C-terminal part of human Reg-alpha and a secondary antibody modified with a photocleavage linker and a reporter peptide detected by MALDI analysis [36] . This study was further improved by using hierarchical clustering based on principal component analysis (PCA) to classify tissues from IMS data, opening interesting possibilities for helping diagnosis [37] . A second potential biomarker, mucin-9, has also been identified. Kang et al. detected specific proteins in tumor interface zones associated with ovarian serous cancer tissues using an approach based on the correlation between IMS and histopathology and the use of PCA [38] . This study confirmed that the tumor interface zones could be differentiated from the tumor and the surrounding normal zones at the molecular level [38] .
Recently, IMS was also used to demonstrate that sulfatides are more abundant in ovarian cancer than control tissues [39] . Interestingly, histological staining is unable to detect the higher sulfatide abundance in ovarian cancer. This study illustrates the potential of IMS for the detection of molecular markers, allowing the diagnosis of early tumors that would be incorrectly classified as normal by histological analysis alone [39] .
Hunt for Breast Cancer Biomarkers
Breast cancer is the leading cause of mortality among women worldwide. It is a complex and heterogeneous disease and includes several subtypes, which have different prognoses and responses to therapy. Recent molecular characterization of some breast cancer subtypes has led to the development of personalized options for treatment targeting, for instance, the estrogen receptor or the HER2 receptor [40, 41] . However, the new targets are broad classifiers and several subtypes of breast cancer tumor are not targeted by these treatments. One of the challenges of breast cancer research, and of proteomic-based research in particular, is to find new protein biomarkers that could distinguish more accurately between subtypes or that could be used for early diagnosis [42, 43] . Again, IMS is promising, as it may identify protein profiles or biomarkers specific to individual tumor types, and could thus be a useful complement to the genetic or histologic approaches currently used in clinical practice [44] .
Several studies have used IMS to study the heterogeneous nature of protein expression in breast cancer tissues associated with specific histological features. Cornett et al. described an automated workflow integrating histopathology with breast tissue profiling by digital imagery, termed histology-directed tissue profiling, to identify specific proteomic profiles according to histological features within breast tumors (stroma, nontransformed epithelium, ductal carcinoma in situ, and invasive mammary cancer) [22] . A further IMS analysis of human breast carcinoma sections showed three proteins to be specifically localized in different regions of the cancer tissue: histone H2A in the ductal carcinoma in situ region, calgizzarin in the invasive carcinoma region, and thymosin b-4 in stroma [45] . IMS of a metastatic breast tumor developing in a lymph node also found protein signals specifically localized in histologically defined regions: m/z 9004 in the advancing edge of the tumor and m/z 5358 in the surrounding normal lymph node, whereas other proteins were ubiquitous throughout the whole tissue section [46] . IMS has also been used to assess the distribution of lipids and cations within breast cancer xenograft models; this work showed that the heterogeneity of breast cancer was not restricted to the proteome [47] . The spatial distribution of choline metabolites and cations, including K þ and Na þ , in two breast cancer xenografts, the noninvasive MCF-7 breast cancer model and the invasive and metastatic MDA-MB-231 breast cancer model, was investigated using a combination of magnetic resonance spectroscopy and IMS. The authors showed that it was possible to distinguish different tumor microenvironments within a tumor type according to the mass distribution of these molecules, and that the two cancer type models displayed different choline metabolite and cation profiles. The diagnostic, prognostic, and therapeutic relevance of this molecular signature needs to be further assessed [47] .
The accurate evaluation of the status of clinical parameters in cases of breast cancer is of primary importance for therapeutic decisions. Thus, a recent study showed the potential 
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of IMS for HER2 status classification of breast cancer based on protein pattern. This potentially allows the selection of patients likely to respond to trastuzumab (Herceptin) treatment (anti-HER2 therapy) [48] . Comparing the HER2þ vs. HER2À breast cancer protein profiles, the authors found a specific proteomic signature of seven m/z species able to accurately classify the HER-2 status with a sensitivity of 83%, a specificity of 92%, and a global accuracy of 89%. One of these peaks of interest, that at m/z 8404, specific to the HER2þ breast cancer subtype was identified as cysteine-rich intestinal protein 1 (CRIP1). These results are in agreement with previous gene expression studies showing a correlation between the amounts of CRIP1 mRNA and HER2 mRNA [49, 50] . Another IMS study comparing breast primary tumors from patients with or without lymph node involvement highlighted six differentially expressed proteins that could predict lymph node status with accuracy greater than 70% [46] . Consequently, the determination of nodal status in primary breast tumor biopsies by testing for a molecular signature could contribute to the decision of whether to dissect lymph nodes at surgery.
Other groups have described the use of IMS to assess druginduced early changes in the tumor proteome that could predict clinical outcome or tumor responsiveness to molecular therapeutics. Mouse mammary tumor virus (MMTV) promoter/HER2 transgenic mice have been used as an in vivo model of metastatic breast tumor to identify protein profiles that predict antitumor action of the erbB receptor inhibitors OSI-774 and Herceptin [51] . Peaks corresponding to thymosin b-4 and ubiquitin were higher and peaks corresponding to an Ecadherin fragment and a calmodulin fragment were lower in OSI-774 and Herceptin-treated than control tumors, and this effect was time and dose dependent and correlated with the tumor reduction. Several peaks, including those for calgranulin and an E-cadherin-binding protein fragment, for example, were up-regulated after Herceptin treatment in sensitive but not resistant tumors. These signals are therefore potential biomarkers of tumor response to Herceptin treatment [51] . Bauer et al. [52] used IMS to find molecular markers predictive of the response to neoadjuvant taxane-based therapy. They showed that detection of m/z species corresponding to alpha-defensins in the pretreatment biopsy samples correlated with the complete pathologic response to combined taxane/radiation and surgery treatment [52] . Immunolocalization of alphadefensins in pretreatment biopsies confirmed the expression of these proteins in tumor cells and in tumor stromal cells was stronger in patients with complete pathologic response than in those with incomplete pathologic response. Alpha-defensin expression was also associated with substantial inflammation and immune cell infiltration in the tumor [52] .
Prostate Cancer Signatures
Prostate cancer is the most common cancer in men over 50 years old and the second leading cause of cancer death in men after lung cancer [53] . The routine serum-based prostate-specific antigen (PSA) test has greatly improved the diagnosis of prostate cancer. However, the false-positive rate is still too high because the specificity of PSA is insufficient for accurate screening [54] . New markers are therefore needed to improve the accuracy of diagnosis. As early as 2001, MALDI mass spectrometry was employed with tissue blotted onto a polyethylene membrane to profile proteins specifically expressed in the different lobes of the mouse prostate [55, 56] . This work showed that signals could be detected from regions where particular proteins were predominantly expressed. In this pre-IMS work, the authors focused on spermine, a prostate-specific protein, mainly found in the ventral lobe of the organ. They investigated the variations of its sequence, relative to the published sequence, and also studied its posttranslational modifications.
The first clinical study of human prostate cancer by IMS was by Schwamborn et al. [57] . The technique allowed the identification of peaks differing between normal and malignant regions of prostate sections. Using pattern recognition algorithms, a sensitive and specific classification model was generated. This work demonstrated the feasibility of classifying human prostate cancer tissues by IMS, giving a classification that can be correlated to histological information. IMS was further used by Chaurand et al. to study the ontogeny of protein expression at different times of development of normal mouse prostate and of prostate tumors [58] . In addition to revealing differential protein expression during tumor development, IMS was also used with success to monitor posttranslational modification events. Thus, overexpression of cyclophilin A (CypA, official symbol PPIA) was demonstrated in various cancers, and it was detected with a differential a-N-terminal acetylation. Both acetylated and nonacetylated CypA isoforms were detected by IMS during normal prostate and mouse prostate tumor development. Interestingly, the authors used IHC and Western blotting to demonstrate significantly more abundant CypA in mouse prostate tumors than in normal tissue. The combination of the three analytical strategies clearly led to a better understanding of normal prostate and prostate cancer development.
More recently, Cazares et al. investigated the potential of IMS for the discovery of new markers of human prostate cancer [59] . Statistical analysis of IMS data demonstrated that a particular m/z ion allowed discrimination between prostate cancer and uninvolved tissue. This ion was identified as a fragment of mitogen-activated kinase kinase kinase 2 (MEKK2, official symbol MAP3K2). Overexpression of MEKK2 in tumor tissue was confirmed using IHC and Western blotting. Interestingly, MEKK2 expression may be correlated to cancer stage/grade. These findings clearly strengthen the argument for integrating IMS analyses into clinical decision-making strategies, and open promising perspectives for the diagnosis of human prostate cancer.
MALDI IMS IN FUNDAMENTAL REPRODUCTIVE RESEARCH
IMS can also be used to help elucidate basic biological issues, and for example contribute to work on embryo implantation or gene expression product profiling during gametogenesis.
Molecular Clues on Embryo Implantation and Development
The molecular events involved in successful embryo implantation are still not well understood. Early failure of pregnancy is often due to defects before, during, or immediately after implantation. Investigation of events during early pregnancy is challenging because of the diversity of cell types in the uterus and the blastocyst involved in embryo implantation. Pioneering work by Burnum and collaborators used IMS to study in situ the proteome profiles of implantation and interimplantation sites in the mouse uterus at various times of pregnancy [60] . Differential proteome profiles were established, distinguishing between the different regions and stages of embryo implantation, leading to the identification of four proteins of interest: ubiquitin, calcyclin, calgizzarin, and transthyretin. These proteins are involved in pregnancy, and were further analyzed because of their unique expression patterns in the uterus. This work demonstrated the potential of LAGARRIGUE ET AL.
IMS to identify proteins playing a critical role in embryo implantation. In a second study, the same group employed IMS to map phospholipid distributions during mouse embryo implantation [61] . Phospholipids are structural components of the membranes but can also act as signaling molecules during embryo implantation. The phospholipid distribution as assessed by IMS changed with time during mouse embryo implantation. Moreover, phospholipid distributions differed between the top and bottom poles of the uterus, implicating the phospholipids involved in the implantation process [61] .
Understanding the Physiology of the Epididymis
The epididymis is divided into three main regions: the caput, the corpus, and the cauda [62] [63] [64] . During their transit through the epididymis, spermatozoa formed in the testis undergo the maturation processes necessary for them to acquire motility and to fertilize. During this transit, there are numerous and complex interactions involving epididymal proteins secreted by the epithelium and accumulated in the lumen of the epididymal tubule. Chaurand and Caprioli [65] , using tissue blotting imaging, were the first to report striking differences between the protein profiles in the caput and the cauda, reflecting highly regionalized protein expression in the mouse epididymis. Interestingly, sensitivity was improved when IMS was performed on fresh frozen tissues rather than tissue imprints on blotting paper [65] . Cells from the intertubule connective tissue, epithelium cells from the epididymal tubule, and secretions from the inside of the tubule were laser microdissected and further analyzed by IMS: a signal at m/z 4965 corresponding to thymosin b-4 [7] was observed only within the cells from the intertubule connective tissue and from the tubule epithelium, whereas a signal at m/z 26833 corresponding to the cysteine-rich secretory protein 1 [66] was detected only in the tubule epithelium cells and in the secretions. IMS on the entire mouse epididymis was even more informative (Fig. 2) [67, 68] . The regionalized expression of proteins on whole longitudinal sections from caput to cauda was clearly visualized by IMS. Clear and basal epithelial cells from the epididymal tubule and secretions from inside the tubule were laser-capture microdissected and analyzed by MALDI mass spectrometry to investigate further the protein composition at the cellular level [67] . The major protein signals displaying a regionalized expression along the tubule were identified using conventional trypsin digestion and liquid chromatography-mass spectrometry/mass spectrometry analysis correlated to IMS data.
Discovering New Molecular Actors of Spermatogenesis
The communication network linking the various cellular activities involved in spermatogenesis is highly complex and 
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sophisticated [69, 70] . Control of this unique differentiation incorporates juxtacrine, paracrine, and endocrine factor information and is conditioned by the successive activation and/or repression of thousands of genes and proteins, including numerous testis-specific isoforms modulating somatic and germ cell activity (for reviews, see [71] [72] [73] [74] ). All these features contribute to make the testis, like the brain, one of the most complex tissues in the body.
The first IMS experiment performed on the testis studied the localization of seminolipids during mouse testis maturation [75] . Seminolipids are synthesized in primary spermatocytes and their expression remains stable during spermatogenesis. It has been suggested that seminolipids are present in the lipid raft [76] and contribute to the sperm cell membrane shape and stability [77, 78] . The role of seminolipids during spermatogenesis is still not completely understood, but they seem to be essential [79] . The IMS study indicated that various seminolipids appeared during testicular maturation: a signal at m/z 767 (C16:0-alkyl-C14:0-acyl) was found at the edge of tubules where spermatogonia and spermatocytes are present, and another at m/z 809 (C17:0-alkyl-C16:0-acyl) was observed in the inner lumen of tubules and was specific to spermatids and spermatozoa. This first study helped determine which lipids contribute to spermatogenesis.
Unraveling aspects of the communication network linking the various cellular activities during spermatogenesis using approaches based on cell culture has always been problematic because of difficulties in culturing more differentiated male germ cell types. The absence of this testing ground places greater emphasis on quality ''-omics'' analyses to allow subsequent in vivo testing of hypotheses. In this context, IMS appears to be an extremely promising technology, as it makes monitoring the protein contents of germ cells feasible directly within the seminiferous tubules. The rat testis, with its anatomical complexity, was used recently as a relevant model by Lagarrigue and collaborators [20] . They combined readily available technologies to visualize, at 20-lm lateral image resolution, different stages of germ cell development in testicular seminiferous tubules and provide a molecular correlate for its well-established stage-specific classification LAGARRIGUE ET AL. (Fig. 3 ). An identification procedure based on total protein extraction from rat testis, reversed phase HPLC fractionation and top-down mass spectrometry analysis was developed to characterize the proteins corresponding to m/z of interest. For example, among numerous identifications, the full-length and singly acetylated thymosin b-10 and thymosin b-4 proteins were characterized, and IHC studies with adult rat testes sections and specific antibodies further confirmed the localization of the proteins as observed on molecular images (Fig. 3) . This pioneer testicular imaging work opens exciting perspectives for the in situ identification of molecular actors important to normal and pathological spermatogenesis. This work also clearly shows that MALDI imaging can provide sufficient lateral resolution for unambiguous correlation with histoanatomical and cytological microscopic images.
The applications of MALDI IMS and their outcomes described in the publications cited above are summarized in Table 1 .
BOTTLENECKS AND PERSPECTIVES OF IMS
IMS has great potential for application to reproductive research. Over the past 10 years, advances in genomics and postgenomics have improved our knowledge in the field. However, many technical challenges remain before IMS is widely exploited by laboratories working on these subjects 
Application
Major outcomes References Breast Histology-directed human breast tissue profiling Specific proteomic profiles according to histological features within the breast tumor cancer (stroma, non-transformed epithelium, ductal carcinoma in situ and invasive mammary cancer) [22] Characterization of different regions of the human breast carcinoma Specific proteins: histone H2A in the ductal carcinoma in situ region, calgizzarin in the invasive carcinoma region and thymosin b-4 in stroma [45] Profile distribution of lipids and cations within MCF-7 and MDA-MB-231 breast cancer xenograft models
Observation of different choline metabolites and cation profiles between the two cancer type models and the different tumor microenvironments within a tumor type model [47] Mouse mammary tumor virus promoter/human HER2 transgenic mice (in vivo model of metastatic breast tumor) treated with the erbB receptor inhibitors OSI-774 and Herceptin
Overexpression of thymosin b-4 and ubiquitin and downexpression of a fragment of E-cadherin and calmodulin in OSI-774 and Herceptin-treated tumors; Overexpression of calgranulin and E-cadherin binding protein fragments in Herceptin-treated sensitive tumor [51] Predictive molecular markers of neoadjuvant taxane-based therapy response in human breast cancer
Correlation between the detection of m/z species corresponding to a-defensins in the pretreatment biopsy samples and the complete pathologic response after taxane/ radiation and surgery treatment [52] Ovary Discovery of potential human ovary carcinoma biomarkers Overexpression of a C-terminal fragment of the proteasome activator complex subunit 1 (Reg-a) in ovary carcinoma [35] Discovery of potential human ovary carcinoma biomarkers Confirmation of the overexpression of the C-terminal fragment of Reg-a and identification of mucin-9 as a second potential biomarker [37] Discovery of potential biomarkers of interface zone of human ovarian tumor
Overexpression of plastin 2 and peroxiredoxin 1 in tumor interface zones of ovarian serous cancer tissues [38] Sulfatides in human ovarian cancer Elevation of sulfatides in ovarian cancer Phospholipid distributions during mouse embryo implantation Detection of specific phospholipid distributions on the top and bottom poles of the uterus [61] Epididymis Proteome profiles in the mouse epididymis Detection of proteins differentially expressed between the caput and the cauda [65] Proteome profiles in the mouse epididymis Detection and identification of proteins differentially expressed between different regions of the whole epididymis [67, 68] Testis IMS of rat testis at 20 lm lateral resolution Detection and identification of proteins specific to germ cells at different stages of their development at 20 lm lateral resolution [20] Seminolipid ditributions during mouse testis maturation Identification of seminolipids appearing in different regions of the seminiferous tubule during testis maturation [75] MALDI IMAGING IN BIOLOGY OF REPRODUCTION (Fig. 4) . Improving the lateral image resolution, currently in the range of 20-80 lm, down to the size of an individual cell ( 10 lm), is key to making IMS more applicable to biological and biomedical research. It is clearly essential for addressing biological questions concerning gametogenesis because of the complex anatomy of the testis and ovary. This is also important in cancer research, where efficient, sensitive, and selective analysis of tumor tissue ultimately requires molecular histological analyses of individual cells (see above). IMS experiments are generally performed at a lateral resolution of 50-80 lm. However, because of the complexity and well-defined morphology of the epididymis, higher resolution IMS imaging would be extremely beneficial for studying the biology of this organ. Using the epididymis as a model, Chaurand et al. made technological developments and designed a modified mass spectrometer capable of IMS at resolution ,10 lm with wide mass range detection capabilities (up to m/z 27 000) [80] . These profiles were found to be reproducible and in good agreement with previously published results. However, the signal quality, in terms of background and signal-to-noise ratio, was lower than that obtained with larger laser spot diameters. These findings clearly indicate that IMS of tissue sections with 10-lm lateral resolution is technically feasible with modified instruments, and show also where efforts should be concentrated to facilitate analysis of single cells.
The acquisition of high-resolution molecular images primarily depends upon an appropriate laser spot diameter and a matrix application method that precludes delocalization of analytes. Higher imaging resolutions are possible only if the matrix is deposited homogeneously, forming a very even and high-density monolayer of crystals (with dimension ,1 lm), without allowing delocalization or migration of compounds from the surface of the sample during the application process. Matrix coating on tissue sections can be substantially improved by optimization of matrix deposition steps and the production of submicron crystals such as those obtained by sieving [81] or sublimation [82, 83] ; further developments in this area would clearly be valuable [84] . The lateral resolution is also theoretically limited to the size of the laser beam, which is generally around 50-100 lm. Interestingly, this limitation has been partially overcome by using an oversampling approach [85] ; however, this approach is associated with a loss of sensitivity and spectral quality. Few instruments have been customized or modified for the acquisition of images at cellular length scales ( 10 lm) [80, 86, 87] . However, recent major improvements in laser technology now allow the acquisition of images at a lateral resolution of 20 lm with commercially available instruments without any significant detrimental effect on the spectral quality [20] .
Another limitation of MALDI imaging is the relatively narrow range of masses detected, typically between 2 and 25 kDa. Indeed, ion detection in time-of-flight mass spectrometers using conventional microchannel plate detectors is a velocitydependent process. The detection of high-mass ions with low velocities is thus disfavored relative to that of low-mass ions. New detectors have been developed to improve the sensitivity of detection of proteins up to 100 kDa on tissue sections [88] . However, the detection of high-mass species by IMS is not only limited by the detector but also by sample preparation. Indeed, several studies have demonstrated the insufficient extraction of high-mass proteins when using conventional matrix solutions. Thus, a modified ''sandwich'' method involving the successive deposition of different matrix solutions containing Triton X-100 and xylene has been developed to improve the solubilization of high-mass proteins. A significant enhancement of the detection in the 25-50-kDa mass range was thereby obtained [89] . The use of organic solvents-1,1,1,3,3,3-Hexafluoro-2-propanol and 2,2,2-trifluoroethanol-has also been reported for the detection of proteins up to 70 kDa [90] . Recently, matrix solutions containing different classes of detergents (SDS, Triton X-100, Tween 20, Tween 80, and CHAPS) at low concentrations were tested for IMS with various organs. With the exception of CHAPS, these detergents improved signal acquisition within the 4-40-kDa mass range without signal suppression or interfering background signals. It seems that the detergent selection should be adjusted according to the organ studied for optimal enhancement [91] .
Identification of proteins detected by IMS is still challenging. Various approaches have been developed based on topdown [20, 59] or bottom-up [35, 60] analysis of tissue homogenates or directly from tissue sections using on-tissue enzymatic digestion [92] or in-source decay [93] . It is currently impossible to reduce the complexity of tissue samples before IMS analysis. Consequently, proteins that are not abundant are very difficult to detect by IMS. Sample complexity is substantially increased by on-tissue digestion of proteins, often used for identification. The use of high-resolution mass spectrometers [94] or coupling with ion mobility [95] may be very helpful to overcome these issues.
The mining of IMS data still has to be improved [96] . The discovery of new candidate biomarkers and the classification of tissues or regions of tissues by IMS require the development of statistical methods adapted to IMS. Finally, the validation of new potential biomarkers on large numbers of samples requires an increase in the throughput of IMS analysis. Currently, the maximum laser shot frequency available on a commercial instrument is 1000 Hz, and this will soon jump up to 3000 Hz. The development of MALDI-TOF mass spectrometers equipped with faster solid-state lasers capable of repetition rates of several kilohertz would therefore be very valuable [97] . This, in turn, requires onboard electronics, fast and precise sample stage movement within the ion source, modules for data acquisition, and storage capacity adapted to such high repetition rates.
Most clinical tissue specimens are conserved as FFPE samples. It was generally believed, until recently, that proteins in FFPE tissues were altered and inaccessible for analysis by mass spectrometry. However, recent developments have shown it is now possible to access the proteins in IMS experiments [25, 26] following antigen retrieval [29] . This breakthrough now allows the exploitation of large collections of FFPE tissues that are associated with long-term clinical data. It will also help alleviate problems commonly associated with frozen tissues, increase the number and quality of samples available for study, and allow the study of precious biological samples. As an example in the reproductive field, we believe that IMS is now the approach of choice for in situ discovery of biomarkers on FFPE testicular carcinoma sections.
CONCLUSIONS
Although many -omics approaches have reached some sort of maturity, proteomics remains, in some ways, the growing child. Partly this has been due to the greater variety of technologies and strategies being explored simultaneously. Burgeoning advances in mass spectrometry imaging will inevitably attract biologists and clinicians as the fruits of this technology become more widely known. However, newcomers to proteomics should proceed with caution as this field remains highly technical. Fortunately, expert platforms are available and can collaborate with providers of high-quality biological material, enabling specialists to concentrate on the biological questions they wish to address.
